Progyny Outperforms Amarantus Bioscience in Financial Review

Analysts see more upside potential in fertility benefits provider Progyny compared to biotech firm Amarantus Bioscience.

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

A financial review comparing medical companies Progyny (NASDAQ:PGNY) and Amarantus Bioscience (OTCMKTS:AMBS) found that Progyny has higher revenue, earnings, and stronger institutional ownership, while also being less volatile than Amarantus. Analysts believe Progyny is the more favorable stock based on its consensus rating and potential upside.

Why it matters

The comparison highlights the contrasting fortunes of the two medical companies, with the fertility benefits provider Progyny outperforming the smaller biotech firm Amarantus Bioscience across key financial metrics. This reflects the growing demand for specialized fertility services and the challenges faced by smaller pharmaceutical companies.

The details

The analysis found that 94.9% of Progyny's shares are held by institutional investors, indicating strong backing from large money managers, hedge funds and endowments. In contrast, only 10.3% of Amarantus Bioscience's shares are held by insiders. Progyny also has higher revenue and earnings per share than Amarantus Bioscience. Additionally, Progyny has a lower beta of 0.96, meaning its stock price is less volatile compared to the S&P 500, while Amarantus Bioscience has a higher beta of 1.61.

  • The financial review was published on February 13, 2026.

The players

Progyny

A benefits management company that specializes in fertility and family building benefits solutions in the United States.

Amarantus Bioscience

A biopharmaceutical company that focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine.

Got photos? Submit your photos here. ›

The takeaway

The financial review highlights the contrasting fortunes of the two medical companies, with the fertility benefits provider Progyny outperforming the smaller biotech firm Amarantus Bioscience. This reflects the growing demand for specialized fertility services and the challenges faced by smaller pharmaceutical companies in the current market environment.